ABEO vs EDIT
ABEO: Abeona is a commercial-stage biopharmaceutical company that just received FDA approval for ZEVASKYN®, the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) wounds. EDIT: A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL receptor upregulation.
Side-by-side fundamentals
| Metric | ABEO | EDIT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.42 | $2.78 | |
| Market cap as of 2026-07-23 | $374M | $421M | |
| P/E as of 2026-07-23 | 5.66 | n/a | |
| Net margin as of 2026-07-23 | +490.4% | -281.6% | ABEO higher |
| Gross margin as of 2026-07-23 | +73.5% | n/a | |
| Operating margin as of 2026-07-23 | +575.2% | -281.3% | ABEO higher |
| ROE as of 2026-07-23 | +41.4% | -677.4% | ABEO higher |
| ROA as of 2026-07-23 | +29.5% | -58.3% | ABEO higher |
| Debt / equity as of 2026-07-23 | 0.12 | 12.40 | ABEO lower |
| Revenue growth (YoY) as of 2026-07-23 | +60.4% | +8.0% | ABEO higher |
| Revenue CAGR (3y) SEC XBRL | +18.0% | +27.1% | EDIT higher |
| Beta as of 2026-07-23 | 1.33 | 2.08 | |
| 1-year return as of 2026-07-22 close | -1.5% | -8.3% | ABEO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.